Co‑Diagnostics expands CRISPR reach

Co‑Diagnostics published the expansion as a company press release dated March 20, 2026, naming CoSara Diagnostics Pvt. Ltd. as the vehicle for the South Asia rollout. (prnewswire.com) CoSara is the Indian joint venture between Co‑Diagnostics and Ambalal Sarabhai Enterprises Limited (ASE Group), and the agreement explicitly adds Bangladesh, Pakistan, Nepal and Sri Lanka to CoSara’s commercial territory. (prnewswire.com) The release specifies CoSara will seek to commercialize the CoSara PCR Pro point‑of‑care instrument and the SARAGENE product line across the newly added countries, with commercialization contingent on each market’s regulatory clearances. (prnewswire.com) Technical materials from Co‑Diagnostics and CoSara describe SARAGENE kits as built on CoPrimers™ real‑time PCR chemistry and list the Co‑Dx PCR Pro as a compact, smartphone‑connected PCR instrument for on‑site multiplex testing. (cosara.in) Operational planning in the announcement includes a virtual distributor briefing in Q2 2026 and an in‑person distributor training session planned for summer 2026, and the JV has previously engaged over 40 distributors domestically during regional conferences. (barchart.com) Financial markets reacted to the news: Co‑Diagnostics shares rose roughly 9% in premarket trading to about $2.90 following publication of the expansion announcement. (computing.net) The company reiterated that product launches will depend on local regulatory authorizations and noted CoSara’s role in assisting clinical performance studies for Co‑Dx PCR Mycobacterium tuberculosis testing, signaling that local lab validation and distributor training will be prerequisites for rollout. (prnewswire.com)